PDCD5在晚期非小细胞肺癌患者血清中的表达及与化疗药物敏感性的相关性研究

目的：研究程序化细胞死亡分子5(PDCD5)在晚期非小细胞肺癌(NSCLC)患者血清中的表达,探讨其与化疗药物敏感性的关系。方法收集经病理证实为晚期 NSCLC 患者40例作为肺癌组,体检健康者20例为正常组。肺癌组给予铂类药物联合其他化疗药物进行化疗,治疗周期为21 d,治疗2周期后进行疗效评估,分为有效组和无效组。采用ELISA 法分别检测肺癌组化疗前后及正常组血清中 PDCD5蛋白的水平,并分析其与疗效、临床特征的关系。结果正常组血清中 PDCD5蛋白的水平高于肺癌组,差异有统计学意义(P <0．05)。化疗前 PDCD5蛋白的水平有效组高于无效组,差异有统计学意义(P <0．05)。化疗后 PDCD5蛋白的水平有效组显著高于无效组,差异有统计学意义( P <0．01)。有效组化疗后 PDCD5蛋白的水平高于化疗前,差异有统计学意义(P <0．05)。无效组化疗后 PDCD5蛋白的水平低于化疗前,差异有统计学意义(P <0．05)。肺癌组血清中 PDCD5蛋白的水平与有无淋巴结转移及肿瘤的分化程度有关(P <0．05),与患者是否吸烟、性别、病理类型均无关(P>0．05)。结论晚期 NSCLC 患者血清中 PDCD5蛋白的水平有望成为化疗敏感性的预测因子,其表达水平降低可能与肺癌的发生有关,也可能为晚期 NSCLC 患者不良预后因素。

The expression of PDCD5 in the serum of patients with advanced NSCLC and the correlation study of its sensitivity to chemotherapy drugs

Objective To investigate the expression level of programmed cell death 5(PDCD5) in advanced non-small cell lung cancer ( NSCLC), and to explore the correlation study of its sensitivity to chemotherapy drugs. Methods 40 advanced non-small cell lung cancer patients were collected and confirmed by pathological examina-tion and designated them as lung cancer group. Another 20 persons whose physical examinations were healthy were collected as normal group. Patients in lung cancer group were given platinum drugs combined with other chemother-apy drugs. The chemotherapy cycle was 21 days and curative effect evaluation was made after 2 cycles of treatment. According to efficacy they were divided into effective group and ineffective group. ELISA was used to detect the ser-um PDCD5 concentration in lung cancer group and normal control group, and its relationship with curative effect and clinical significance was analysed. Results The serum PDCD5 protein level in the normal group was higher than the lung cancer group and the difference was statistically (P < 0. 05). Before chemotherapy the serum PDCD5 protein concentration in effective chemotherapy group was higher than the ineffective group, and the difference was statistically (P < 0. 05). After chemotherapy the PDCD5 protein level difference was dramatically increased be-tween the effective group and the ineffective group, and the difference was statistically significant (P < 0. 01). Af-ter chemotherapy effective group PDCD5 protein level was higher than before, the difference was statistically signifi-cant (P < 0. 05). After chemotherapy ineffective group PDCD5 protein level was lower than before, the difference was statistically significant (P < 0. 05). PDCD5 protein level was associated with lymph node metastasis and differ-entiated degree (P < 0. 05). It was not correlated with gender, pathological type and smoking history (P > 0. 05). Conclusion PDCD5 protein level in serum of patients with advanced NSCLC is expected to be a predictor of che-mosensitivity. The down-regulation of PDCD5 expression level may be associated with the occurrence of lung cancer and may be an adverse prognostic factor of Advanced NSCLC patients.